Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Saniona AB: Saniona AB's Nomination Committee for the 2018 Annual General Meeting | ||
By: Nasdaq / GlobeNewswire - 23 Nov 2017 | Back to overview list |
|
PRESS RELEASE November 23, 2017 The Annual General Meeting on May 23, 2017, resolved that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall comprise three members, which should be representative for the two largest shareholders as of last September, together with the Chairman of the Board of Directors. On September 30, 2017, the two largest shareholders, which desired to appoint a representative to the Nomination Committee, were Jørgen Drejer and Thomas Feldthus. Each such shareholder has appointed a representative, as shown below, who together with the Chairman of the Board of Directors will form Saniona AB's Nomination Committee. The Nomination Committee's member are:
The Nomination Committee shall prepare and submit proposals to the 2018 Annual General Meeting regarding:
The instruction and charter for the Nomination Committee in Saniona AB can be found in the Corporate Governance section at the company's website, www.saniona.com . Saniona AB's Annual General Meeting will be held on Tuesday May 24, 2018 in Malmö. Shareholders who would like to submit proposals to the Nomination Committee can do so via e-mail to tf@saniona.com marked "Recommendation to the Nomination Committee" or by ordinary mail to the address:
Recommendation to the Nomination Committee
To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than 15 February 2018. For more information, please contact Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on November 23, 2017. About Saniona Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq Stockholm Small Cap and has about 5,300 shareholders. The company's share is traded under the ticker SANION. Read more at www.saniona.com .
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Saniona AB via GlobeNewswire
HUG#2151457
|
||
|
||
Copyright 2017 Nasdaq / GlobeNewswire | Back to overview list |